



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

## **Cais Rhyddid Gwybodaeth / Freedom of Information request** **Ein Cyf / Our Ref: 23-A-048**

Please note that we have provided this information for calendar year 2022.

### **You asked:**

#### **1. In the last 12 months, how many patients have been treated (for any condition) with the following drugs?**

- Amphotericin B (Ambisome) - 20
- Caspofungin (Cancidas) - 61
- Isavuconazole (Cresemba) - <5
- Posaconazole (Noxafil) - 37
- Voriconazole (VFEND) - 51

#### **2. In the last 12 months, how many hospital inpatients were diagnosed with Aspergillois (ICD10 code: B44)?**

We have provided the number of individual patients admitted in 2022 with a diagnosis of Aspergilliosis at any point during their inpatient stay.

14 patients

#### **b. Of the above patients diagnosed with Aspergillois in the last 12 months, how many patients were treated with the following drugs:**

- Amphotericin B (Ambisome)
- Caspofungin (Cancidas)
- Isavuconazole (Cresemba)
- Posaconazole (Noxafil)
- Voriconazole (VFEND)

I can confirm that our Pharmacy systems do not hold information to diagnosis level. To obtain this information would involve a manual trawl and search of records which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act and The Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulation 2004 provides that we are not obliged to spend in excess of 18 hours



in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

**3. In the last 12 months, how many hospital inpatients were diagnosed with Mucormycosis (ICD10 code: B46)?**

I can confirm that the Health Board did not have any individual patients admitted in 2022 with a diagnosis of Mucormycosis at any point during their inpatient stay.

**b. Of the above patients diagnosed with Mucormycosis in the last 12 months, how many patients were treated with the following drugs:**

- Amphotericin B (Ambisome)
- Isavuconazole (Cresemba)
- Posaconazole (Noxafil)

Not applicable

---

